• The NWHN statement on the Title X Gag Rule taking effect
    June 24, 2019
    Last year, the Trump-Pence administration rushed through a proposed rule to gut Title X, the country’s family planning program to help low-income individuals access affordable birth control and reproductive health care. Today, a federal appeals court overturned three lower courts and allowed the Title X gag rule to go into effect. This is a devastating ...
  • The NWHN’s Statement on the FDA’s approval of Vyleesi
    June 21, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: 425-749-1886 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C. — The National Women’s Health Network (the NWHN) is disappointed in the United States Food and Drug Administration’s (FDA) decision to approve the drug bremelanotide (brand name: Vyleesi) and urges women to ...
  • Women’s health groups to Congress: We need strong cosmetics standards
    June 20, 2019
    For Immediate Release Contact: Evita Almassi, ealmassi@nwhn.org Washington, D.C. –  Led by the National Women’s Health Network, 42 national, state, and local organizations united by their shared interest in lifting up the voices of women sent a letter today to the House Energy and Commerce Committee applauding the committee for working on a bipartisan discussion draft  to ...
  • The NWHN’s statement on the results of the Evidence for Contraceptive Options and HIV trial (ECHO)
    June 14, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. The National Women’s Health Network (The NWHN) is pleased that the results of the ECHO trial provide reassuring evidence that Depo Provera does NOT significantly increase the risk of HIV infection when compared to ...
  • The NWHN’s statement on the FDA ordering manufacturers of surgical mesh to stop selling devices for uterine prolapse
    April 16, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240   The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington, D.C. — Today, the U.S. Food and Drug Administration ordered the manufacturers of all remaining surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse (POP) to stop selling and ...
  • The NWHN’s statement on the FDA ordering Sprout Pharmaceuticals to retain black box label warning women not mix Addyi and alcohol
    April 12, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C. —  Yesterday the U.S. Food and Drug Administration ordered Sprout Pharmaceuticals to update the label of their female libido pill, flibanserin (brand name: Addyi). The label change says women should ...
  • The NWHN’s statement in response to FDA approving Evenity
    April 10, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org  Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C.- Yesterday, the US Food and Drug Administration approved a new treatment romosozumab, brand name Evenity, from drugmakers Amgen and UCB for osteoporosis in postmenopausal women who are at high risk ...
  • The NWHN advises women to be cautious about using flibanserin until new studies are fully vetted
    March 26, 2019
      The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. WASHINGTON D.C. — Women should not use flibanserin or any drug unless they have sufficient information to weigh benefits against risks. Sprout Pharmaceuticals’ new alcohol studies should be reviewed with a healthy skepticism, until they have been vetted ...
  • NWHN statement in response to the FDA’s action against Aid Access
    March 12, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C.- In a letter released Tuesday, the FDA warned online abortion pill provider AidAccess.org to immediately stop importing mifepristone and misoprostol, the two drugs that make up the most ...
  • The NWHN’s statement on the resignation of FDA Commissioner Scott Gottlieb 
    March 5, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org  Telephone: (202) 682-6240  The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.  Washington D.C.- Today, US Food and Drug Administration Commissioner Scott Gottlieb announced his plan to leave the FDA in about a month.   Prior to his confirmation, the NWHN raised concerns about Gottlieb’s approach to women’s health, his close ties to the pharmaceutical industry, and ...